HC Wainwright Has Positive Outlook for LXEO Q1 Earnings

Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Free Report) - Stock analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Lexeo Therapeutics in a report issued on Wednesday, March 26th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.78) per share for the quarter, up from their previous estimate of ($0.93). HC Wainwright currently has a "Buy" rating and a $23.00 target price on the stock. The consensus estimate for Lexeo Therapeutics' current full-year earnings is ($3.14) per share. HC Wainwright also issued estimates for Lexeo Therapeutics' Q2 2025 earnings at ($0.80) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.66) EPS and FY2025 earnings at ($2.95) EPS.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.87) by $0.09.

LXEO has been the topic of several other research reports. Chardan Capital reaffirmed a "buy" rating and issued a $25.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, March 25th. Leerink Partners reduced their target price on Lexeo Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Monday, March 24th. Finally, Royal Bank of Canada dropped their price target on Lexeo Therapeutics from $24.00 to $20.00 and set an "outperform" rating for the company in a research report on Tuesday, March 25th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $22.80.

Remove Ads

Lexeo Therapeutics Price Performance

Shares of LXEO traded down $0.43 on Friday, reaching $3.04. The stock had a trading volume of 281,237 shares, compared to its average volume of 346,065. Lexeo Therapeutics has a twelve month low of $2.32 and a twelve month high of $19.50. The firm has a market capitalization of $100.95 million, a PE ratio of -0.96 and a beta of 3.85. The firm has a 50-day moving average of $4.02 and a 200 day moving average of $6.49. The company has a quick ratio of 5.95, a current ratio of 5.95 and a debt-to-equity ratio of 0.01.

Institutional Trading of Lexeo Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of LXEO. Allostery Investments LP acquired a new stake in Lexeo Therapeutics in the fourth quarter worth $33,000. BNP Paribas Financial Markets grew its position in shares of Lexeo Therapeutics by 184.2% during the third quarter. BNP Paribas Financial Markets now owns 5,541 shares of the company's stock worth $50,000 after acquiring an additional 3,591 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Lexeo Therapeutics during the fourth quarter worth about $46,000. JPMorgan Chase & Co. increased its holdings in shares of Lexeo Therapeutics by 135.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 10,278 shares of the company's stock worth $93,000 after acquiring an additional 5,915 shares during the period. Finally, Price T Rowe Associates Inc. MD bought a new stake in Lexeo Therapeutics in the 4th quarter valued at about $69,000. 60.67% of the stock is owned by institutional investors and hedge funds.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.